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Abstract
Introduction: A continued need exists for effective diagnostic biomarkers in bacterial sepsis among critically ill patients,
despite increasing use of available biomarkers such as procalcitonin (PCT). Interleukin-27 (IL-27) has shown early promise
in a recent preliminary study, exhibiting high specificity and positive predictive values for bacterial infection in critically ill
children. This validation study was performed to assess the value of IL-27 in predicting bacterial infection among patients
admitted to the pediatric intensive care unit and to compare its performance with that of PCT.
Methods: A single-center (n = 702) prospective study was performed comparing both IL-27 and PCT levels between
bacterially infected and uninfected cohorts in the pediatric intensive care unit. Infected status was determined by a chart
review by an intensivist blinded to biomarker results. Formal performance comparisons included calculations of receiver
operating characteristic (ROC) curves for IL-27 and PCT individually in addition to a combination strategy using a decision
tree generated by classification and regression tree (CART) methodology. Secondary analysis focusing on subjects with
documented bloodstream infections was performed.
Results: The overall infection rate was 27 %. ROC curves for the primary analysis yielded areas under the curve (AUCs) of
0.64 (0.59 to 0.68) for IL-27 and 0.61 (0.56 to 0.65) for PCT. Secondary analysis defining infected status exclusively through
positive blood cultures yielded AUCs of 0.75 (0.68 to 0.81) for IL-27 and 0.64 (0.57 to 0.71) for PCT, with a specificity of
95 % (92 % to 97 %) for the prior established IL-27 cut-point value of at least 5.0 ng/ml. Similar AUCs were found for
the subset of immunocompromised patients. In a CART-derived analysis taking immunocompromised status into
consideration, a combination of IL-27 and PCT yielded an AUC of 0.81 (0.75 to 0.86), statistically improved from either
IL-27 or PCT alone.
Conclusions: Despite having a modest predictive value for infection independent of source, IL-27 may serve as a useful
biomarker in estimating risk of bacterial infection among critically ill pediatric patients with bloodstream infections. In
particular, among immunocompromised subjects, this diagnostic biomarker may be helpful either alone or using a
combination strategy with other available biomarkers.
Introduction
Sepsis is thought to be the leading cause of death in the
pediatric population, and mortality was recently estimated
to be 1.6 million infants and children per year worldwide.
In the US alone, more than 75,000 cases of pediatric severe
sepsis are estimated annually with an in-hospital mortality
of 14.4 % [1–5]. Although the gold standard for diagnosing
sepsis remains positive microbiological cultures, delays
from time of acquisition to final result have led many inves-
tigators to explore the use of sepsis diagnostic biomarkers
as early indicators of infection. In this context, recognizing
bacterial forms of sepsis early is critical because it warrants
prompt antibiotic therapy, and delays in antibiotic adminis-
tration in patients with bacterial sepsis have been shown to
have negative consequences for outcome. Thus, using
bacteria-specific biomarkers for earlier detection, and there-
fore more timely and appropriate treatment, could prove of
great benefit in decreasing both mortality- and morbidity-
related to bacterial sepsis [6–9].
Among current biomarkers used in sepsis, procalcitonin
(PCT) remains one of the more used, despite its variability
in performance depending on patient population and
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despite a recent meta-analysis in adults showing a lack
of reliability in distinguishing infected from uninfected
patients in critically ill cohorts [10–12]. Other biomar-
kers—such as triggering receptor expressed on myeloid
cells-1 (TREM-1), soluble urokinase-type plasminogen
activator receptor (suPAR), and CD64 [13, 14]—continue
to be tested. Recent studies suggest interleukin-27 (IL-27)
as another candidate sepsis diagnostic biomarker [15–17].
IL-27 is a heterodimeric cytokine composed of the
Epstein-Barr virus-induced gene 3 (EBI3, also known as
IL-27B) and the IL27-p28 subunits [18]. IL-27 is produced
by antigen-presenting cells upon exposure to microbial-
derived molecules and inflammatory stimuli [19–21].
Using a large genome-wide expression database of critic-
ally ill children admitted to pediatric intensive care units
(PICUs) across the US, 100 class predictor genes, differen-
tially expressed between patients with and without bacterial
sepsis, were isolated by using computer-assisted image
analysis of gene arrays [15]. Of these 100 predictor genes,
EBI3, a subunit of IL-27, was discovered as having the high-
est predictive strength for bacterial infection. Both IL-27
and PCT concentrations were then measured within a
cohort of 231 critically ill children. Findings included a spe-
cificity and positive predictive value of more than 90 % for
bacterial infection in those with IL-27 levels of at least
5 ng/ml performing significantly better than PCT [15].
Given this, the dearth of other pediatric studies investigat-
ing the value of IL-27, for this purpose, and the need for
more effective biomarkers in bacterial sepsis, we hypothe-
sized that IL-27 can effectively serve as a diagnostic
biomarker among the critically ill pediatric population.
Methods
The study protocol was approved by the Institutional
Review Board of Cincinnati Children’s Hospital Medical
Center (CCHMC). Following this, we performed a pro-
spective cohort study of patients admitted to the CCHMC
PICU with suspected infection between April of 2013 and
December 2014.
Inclusion criteria
Two criteria were required for study eligibility. The first
was admission to the PICU with clinical suspicion for
infection. This clinical suspicion was defined by the acqui-
sition of a blood culture at any point during admission by
the primary ICU team, performed independently and
without interference from the research team. This prag-
matic approach captures the exact context in which a
diagnostic biomarker would be used by clinicians (i.e.,
patients with a clinical suspicion of bacterial infection),
one that may lead to more generalizable results as
compared with a study based on more stringently selected
patients. The second was the availability of a residual
blood sample within 6 hours of blood culture acquisition,
obtained via waiver of informed consent. No exclusion
criteria were used.
Study procedures
Using the CCHMC electronic medical record, the investi-
gating team was notified daily of all blood cultures sent
within the prior 24 hours in the ICU. It was then deter-
mined which of these patients had a residual, otherwise to
be discarded, serum sample within this same time frame
in the CCHMC clinical laboratory. These samples were
obtained from the lab and used to measure both IL-27
and PCT levels by using the magnetic bead multi-plex
platform (EMD Millipore Corporation, Billerica, MA,
USA) and Luminex 100/200 System (Luminex Corpor-
ation, Austin, TX, USA). The IL-27 assay detects the p28
subunit of IL-27. We did not possess the suitable reagents
to measure the related cytokine, IL-35, which consists of
the EBI3 and IL12A subunits [15, 22].
Determination of bacterial infection
Bacterial infection was defined by using both laboratory
and clinical data. All final patient classifications were
determined by using a majority rule among three intensi-
vists, all blinded to biomarker results. Patients designated
as “infected” included all patients with clinically relevant
positive bacterial microbiological cultures collected within
48 hours of enrollment. For the primary analysis, these
cultures included blood, urine, cerebrospinal, pleural,
peritoneal, stool, wound, and endotracheal/tracheal tube
cultures. Of note, those patients with strong evidence for
bacterial infection in the absence of positive cultures were
also included in the “infected” designation. These cases in-
cluded such findings as radiographic evidence (computed
tomography scan, chest x-ray, etc.) or physical exam
findings strongly suggesting bacterial infection in the
absence of positive cultures. All other subjects were classi-
fied as “non-infected”.
Data collection
In addition to the IL-27 and PCT measurements,
relevant demographic data collected included age,
gender, reason for admission, type of admission (sur-
gical versus medical), presence of co-morbidities,
evidence of pre-existing immune suppression, severity
of illness scoring using the Pediatric Risk of Mortal-
ity III (PRISM III) score, and both source and
etiology of infection. Evidence of immune suppres-
sion was determined by a chart review by an intensi-
vist blinded to biomarker results and using data such
as use of chronic immunosuppressive medications
and evidence of conditions commonly associated with
immune-dysregulation.
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Sample size calculation
Using data from the previously published preliminary
study [15], we proposed a sample size 700 ICU patients.
A main goal of this is to estimate the precision of speci-
ficity and sensitivity estimates for IL-27 as a biomarker
for bacterial infection. Assuming an expected prevalence
of approximately 20 % and a specificity of 92 % as
reflected in our preliminary study, 700 patients would
result in 95 % confidence interval (CI) for the estimated
specificity of ± 2 %. The same sample size will also give a
95 % CI of ± 8 % for the sensitivity of 62 %. Given the
above preliminary data, we anticipated data collection to
span roughly 20 months.
Because PCT is currently being used clinically as a
diagnostic biomarker for bacterial infection, the primary
analysis also included a comparison of IL-27 performance
with PCT performance, using calculations of respective
receiver operating characteristic (ROC) curves. For a com-
parison of the areas under the curve (AUCs) for IL-27
with that for PCT, assuming areas of about 0.80 and 0.75
as found in our preliminary studies, 700 patients were
calculated to provide 90 % power to find the difference,
assuming an α of 0.05 and a prevalence of bacterial infec-
tion of 20 %.
Statistical analysis
Using SigmaStat Software (Systat Software Inc., San Jose,
CA, USA), all continuous variables were presented as
median values and categorical variables as percentages.
Statistical tests used to compare study cohorts included
Pearson chi-square and Mann-Whitney rank sum tests.
Multiple logistic regression was performed to assess inde-
pendent contributions of PRISM III scores and IL-27
levels on infection status. ROC curve analysis was also
performed for both IL-27 and PCT. Test characteristics
and their respective 95 % CIs were calculated by using
diagnostic test statistics provided by the VassarStats
Website for Statistical Computation. In our initial report,
the AUC for IL-27 for distinguishing bacterial infection
from sterile inflammation was 0.81 (95 % CI 0.75–0.87)
[15]. Accordingly, we considered a priori that successful
validation of IL-27 as a sepsis diagnostic biomarker would
be reflected by an AUC falling within this CI. Classifica-
tion and regression tree (CART) analysis (Salford Predict-
ive Modeler version 6.6; Salford Systems, San Diego, CA,
USA) was used in the secondary analysis [23].
Results
Demographics
Table 1 shows the demographic and clinical characteristics
of the study cohort. In total, 702 patients, having a median
age of 5.3 (interquartile range of 1.2–13.5) years, were
analyzed. Twenty-seven percent (n = 191) of the patients
were determined to be infected: 76 % had positive cultures
and 24 % negative cultures. Among those with positive
cultures, 46 % were isolated from the blood, 24 % from
the respiratory tract (including samples from endotracheal
aspirates and bronchoalveolar lavage), and 19 % from the
urinary tract. Although PRISM III scores were signifi-
cantly higher among infected compared with uninfected
patients, results of multiple regression analysis using both
PRISM III scores and IL-27 levels as independent variables
suggest that IL-27 is positively related to infection
status independently of severity of illness (Wald’s χ2
5.8, P = 0.02).
Primary analysis
Differences in median values between infected and unin-
fected groups were significant for both IL-27 (1.7 versus
1.2 ng/ml, P <0.001) and PCT (7.0 versus 6.4 ng/ml, P <
0.001). ROC curves generated resulted in AUCs of 0.64
(0.59, 0.68, P < 0.001) for IL-27 and 0.61 (0.56, 0.65, P <
0.001) for PCT. The area difference between the AUCs
was not significant. See Fig. 1 for the ROC curve and
Table 2 for the associated test characteristics.
Secondary analysis
Given that the infected patients in the prior pediatric
study primarily included patients with positive blood
cultures, a secondary analysis was performed by using a
definition of infection that included only patients with
clinically relevant positive blood cultures. Five hundred
seventy-nine patients were included, 68 (12 %) of whom
were classified as infected exclusively on the basis of blood
cultures. ROC curves yielded AUCs of 0.75 (0.68–0.81) for
IL-27 and 0.64 (0.57–0.71) for PCT, with an area
difference of 0.10 (P = 0.02) (Fig. 2). Using this definition
of infection and the prior cut-point of 5 ng/ml for IL-27,
test characteristics included a specificity of 95 % (93–97)
and a positive predictive value of 47 % (32–62) (Additional
file 1). Further analysis focused on the subclass of patients
classified as immune-suppressed (n = 182) revealed similar
AUCs of 0.75 (0.64–0.85) and 0.67 (0.56–0.78) for IL-27
and PCT, respectively.
A subsequent CART analysis was generated by using this
same modified definition which included IL-27 levels, PCT
levels, and immunocompromised status as predictor vari-
ables (Fig. 3). Starting with the “root” node that included
all patients (n = 579) and dividing into two subsequent
“daughter” nodes, eight terminal nodes were ultimately
generated, each with specific cutoff points for IL-27 and
PCT. Terminal nodes 1, 3, and 5 were designated as low-
risk nodes with 3 %, 4 %, and 0 % of patients being
infected, respectively. Terminal nodes 2, 4, 6, 7, and 8 were
designated as higher-risk nodes compared with the “root”
node, with rates of 12 %, 29 %, 25 %, 38 %, and 86 %,
respectively. Using these designations, the CART algorithm
was then tested, yielding an AUC of 0.81 (0.75, 0.86). This
Hanna et al. Critical Care  (2015) 19:378 Page 3 of 7
was statistically improved from both the individual IL-27
(0.81 versus 0.74, P < 0.01) and PCT (0.81 versus 0.64,
P <0.01) AUCs (Additional file 2). Test characteristics
(95 % CI) for the tree yielded a sensitivity of 84 %
(72–91), specificity of 63 % (59–67), negative predictive
value of 97 % (94–98), positive predictive value of 23 %
(18–29), positive likelihood ratio of 2.3 (1.9–2.6), and
negative likelihood ratio of 0.3 (0.2–0.4).
Discussion
We prospectively tested the diagnostic utility of IL-27 as a
sepsis diagnostic biomarker in a heterogeneous cohort of
critically ill children. In the primary analysis, both IL-27
and PCT demonstrated poor reliability for estimating
bacterial infection risk, as determined by a priori criteria
based on the previously published ROC curve [15]. A
trend to improvement was noted, however, when a
secondary analysis was performed by using a modified
definition of infection that included only those patients
found to have positive blood cultures, and IL-27 was
found to have a significantly better predictive value when
compared with PCT. With this definition, an IL-27 cutoff
value of at least 5 ng/ml was also noted to have a similar
diagnostic value as a “rule in” test to the original study,
exhibiting a specificity of 95 % [15]. The lower positive
predictive value may be explained by a lower prevalence
of positive cases, as the prior study exhibited a prevalence
of positive cases nearly five times (56 %) the current
cohort [15]. Lastly, a CART-generated algorithm that
included IL-27, PCT, and immune-compromised status
led to a statistically significant trend toward improvement
in predictive value.
Our results suggest that IL-27 has a greater predictive
value in patients with positive bloodstream infections
compared with infections from other body compartments.
These results are consistent with the original pediatric
Table 1 Demographic characteristics of the study groups
Infected Uninfected P value
Age, years (IQR) 8.2 (1.6–15.1) 4.9 (IQR 1.1–12.4) 0.003
% males 51 58 0.13
% immune-suppressed state 27 30 0.37
% post-operative admission 9 13 0.27
% co-morbidities 77 72 0.27
Median IL-27 concentration, ng/ml (IQR) 1.7 (0.9–3.2) 1.2 (0.8–0.6–2.0) <0.001
Median PCT concentration, ng/ml (IQR) 7.0 (5.7–9.4) 6.4 (5.3–8.0) <0.001
Median minutes between culture and IL-27 specimen (IQR) 8.2 (1.6–15.1) 4.9 (1.1–12.4) 0.003
Median PRISM III score (IQR) 6 (2.8–12.0) 3 (0–8) <0.001
IQR interquartile range, IL-27 interleukin-27, PCT procalcitonin, PRISM III Pediatric Risk of Mortality III
Fig. 1 Receiver operating characteristic (ROC) curve for bacterially infected versus uninfected patients in the primary analysis. The procalcitonin
(PCT) curve is shown in grey and the interleukin-27 (IL-27) curve in black
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study in which the majority of positive cases involved
patients with positive blood cultures [15]. Moreover, two
recent adult studies have shown improved predictive
values of IL-27 when excluding pulmonary sources of
infection from the “infected” definition [16, 17]. The bio-
logical basis of these findings may be related to increased
immune upregulation associated with systemic infection
but is unclear and warrants further investigation. Alterna-
tively, given that recent population-based studies indicate
a bacterial etiology in only roughly 8 % of children with
clinically and radiographically diagnosed pneumonia,
concerns of misclassification bias may be more heightened
among such populations as these [24]. We have attempted
to minimize this concern by using three independent
intensivists in the classification process. Nevertheless, by
classifying only patients with clinically relevant culture-
positive bloodstream infections as “infected” and using
those with no concerns for infection as a comparator, this
bias may have been further minimized.
Although conclusions are limited by a relatively small
number of infected patients, the predictive value of IL-27
among the subset of immunocompromised patients is an
interesting finding. That immunocompromised status
among other demographic variables was included in the
decision tree also suggests IL-27 may yet play a significant
diagnostic role in this population. Of note, more than 80 %
of those patients designated as immune-compromised were
being administered immunosuppressive medications and
roughly 50 % had a diagnosis requiring bone marrow or
solid organ transplantation. Although IL-27, produced by
antigen-presenting cells upon stimulation by microbial
products [18, 21], might be thought of as less predictive
among populations in which such cells are compromised,
such a perspective likely greatly simplifies the picture. Both
the complex pleotropic nature of IL-27 and the vast variety
of immunopathology combined under the heading of
“immune compromised” warrant further elucidation.
Notable limitations to our study include lack of data
regarding temporal production of IL-27. By selecting
blood samples for analysis no later than 6 hours following
blood culture acquisition, we have attempted to minimize
this. Median times from blood culture to biomarker
Table 2 Test characteristics for predicting bacterial infection
IL-27, ≥ng/ml Sensitivity Specificity NPV PPV
2.0 43 % (36–51) 76 % (72–80) 71 % (67–74) 29 %(26–33)
3.0 27 % (21–34) 91 % (88–93) 77 % (73–80) 52 % (42–63)
4.0 20 % (15–26) 94 % (91–96) 76 % (72–79) 54 % (42–66)
5.0 12 % (8–17) 95 % (93–97) 74 % (71–77) 47 % (32–62)
6.0 8 % (5–13) 96 % (94–98) 74 % (70–77) 46 % (29–63)
IL-27 interleukin-17, NPV negative predictive value, PPV positive predictive value
Fig. 2 Receiver operating characteristic (ROC) curve for bacterially infected versus uninfected patients in the secondary analysis. The definition of
infected includes those patients with blood culture-positive bacterial infections. The procalcitonin (PCT) curve is shown in grey and the interleukin-27
(IL-27) curve in black
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specimen acquisition were less than 10 minutes for both
infected and uninfected cohorts (Table 1). In addition, the
study was not adequately powered to conclusively com-
ment on the predictive trend among immunocompromised
patients. Further studies may be warranted in this popula-
tion. Lastly, among the potential confounding variables,
severity-of-illness scores were found to be significantly
higher in the infected cohort. However, this was accounted
for by regression analysis that established IL-27 levels as an
independent predictor of infected status.
Conclusions
Our results suggest that IL-27 may serve as a useful
biomarker in estimating risk of bacterial infection
among critically ill pediatric patients with bloodstream
infections. In particular, among those classified as
immune-compromised, this diagnostic biomarker may
be helpful either alone or using a combination strategy
with other available biomarkers, although further
research is warranted.
Key messages
 Despite having modest predictive value for all
bacterial infections, interleukin-27 may serve as a
useful diagnostic biomarker among critically ill
children with bloodstream infections.
 Interleukin-27 outperformed procalcitonin in the
subgroup of patients with bloodstream infections.
 A combination strategy including both biomarkers
may aid in the early diagnosis of bacterial infection
among immunocompromised patients.
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